AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T15:44:00Z
Is UTL A Good Stock To Buy Now?
Sat 12 Dec 20, 02:24 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 61.43M | -4.54800M | 22.68M | 22.00M | 34.04M |
| Minority interest | - | - | - | - | - |
| Net income | 35.64M | -8.62700M | 11.99M | 14.31M | 31.90M |
| Selling general administrative | 106.63M | 75.32M | 78.60M | 76.37M | 60.51M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 221.67M | 129.37M | 142.34M | 135.00M | 151.40M |
| Reconciled depreciation | 12.02M | 3.76M | 4.77M | 4.65M | 3.67M |
| Ebit | 53.45M | -2.91300M | 25.25M | 21.82M | 46.63M |
| Ebitda | 65.48M | 0.85M | 30.02M | 29.34M | 50.30M |
| Depreciation and amortization | 12.02M | 3.76M | 4.77M | 7.52M | 3.67M |
| Non operating income net other | -15.48200M | -5.68200M | -7.70000M | 2.87M | 0.16M |
| Operating income | 53.45M | -2.91300M | 25.25M | 21.82M | 36.62M |
| Other operating expenses | 235.65M | 168.78M | 154.85M | 174.08M | 166.84M |
| Interest expense | 4.04M | 1.64M | 2.58M | 2.69M | 2.74M |
| Tax provision | 25.79M | 4.08M | 10.69M | 7.68M | 2.13M |
| Interest income | 0.27M | 0.56M | 0.56M | 2.17M | 0.16M |
| Net interest income | -3.77400M | -1.07500M | -2.01500M | -0.51700M | -2.57800M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | 9.48M | 10.65M | 11.82M | 13.01M | 30.16M |
| Other items | - | - | - | - | - |
| Income tax expense | 25.79M | 4.08M | 10.69M | 7.68M | 2.13M |
| Total revenue | 316.61M | 171.55M | 187.80M | 195.89M | 213.31M |
| Total operating expenses | 140.71M | 126.60M | 109.38M | 113.18M | 104.93M |
| Cost of revenue | 94.94M | 42.18M | 45.47M | 60.90M | 61.92M |
| Total other income expense net | 7.98M | -1.63500M | -2.57700M | 0.18M | -9.85200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 35.64M | -8.62700M | 11.99M | 14.31M | 31.90M |
| Net income applicable to common shares | 35.64M | -8.62700M | 11.99M | 14.31M | 31.90M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 406.16M | 253.73M | 253.19M | 254.55M | 238.60M |
| Intangible assets | 118.33M | 10.67M | 12.92M | 15.58M | 18.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 13.20M | 11.89M | 1.60M | 15.10M | 10.26M |
| Total liab | 172.60M | 77.28M | 67.18M | 75.38M | 77.84M |
| Total stockholder equity | 233.56M | 176.45M | 186.01M | 179.17M | 160.76M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 85.84M | 6.97M | 3.08M | 2.30M | 1.81M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | 111.50M | 75.86M | 84.49M | 72.50M | 58.19M |
| Other liab | 3.79M | 2.90M | 3.96M | 3.00M | - |
| Good will | 45.03M | 39.74M | 39.74M | 39.74M | 39.74M |
| Other assets | 52.88M | 29.08M | 32.39M | 13.86M | 14.52M |
| Cash | 55.32M | 97.66M | 103.16M | 109.78M | 78.79M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 111.09M | 74.38M | 38.09M | 38.82M | 39.69M |
| Current deferred revenue | - | 25.36M | 20.74M | 26.06M | 21.71M |
| Net debt | 7.14M | -72.05200M | -66.06100M | -71.21800M | -34.38600M |
| Short term debt | 6.25M | 25.61M | 8.00M | 5.00M | 6.25M |
| Short long term debt | 6.25M | 25.61M | 8.00M | 5.00M | 6.25M |
| Short long term debt total | 62.47M | 25.61M | 37.09M | 38.56M | 44.41M |
| Other stockholder equity | 123.15M | 100.67M | 101.50M | 106.66M | 102.56M |
| Property plant equipment | 1.17M | 1.64M | 2.08M | 2.20M | 2.40M |
| Total current assets | 188.75M | 172.61M | 166.06M | 179.45M | 163.84M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 70.20M | 126.04M | 133.35M | 123.85M | 102.92M |
| Short term investments | - | - | - | - | - |
| Net receivables | 72.44M | 41.15M | 51.12M | 48.00M | 66.49M |
| Long term debt | 56.22M | - | 25.14M | 33.56M | 38.16M |
| Inventory | 47.79M | 21.91M | 8.07M | 6.57M | 8.30M |
| Accounts payable | 18.99M | 16.43M | 6.27M | 5.46M | 9.92M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.11200M | -0.09400M | - | -4.31900M | -3.34700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 111.50M | 75.86M | 84.49M | 72.50M | 58.19M |
| Treasury stock | -243.11500M | -225.11100M | -203.89800M | -171.86100M | -153.90000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 25.73M | 10.28M | 17.21M | 3.91M | 0.69M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 217.41M | 81.13M | 87.12M | 75.11M | 74.76M |
| Capital lease obligations | 5.32M | 4.21M | 3.96M | 3.00M | - |
| Long term debt total | 56.22M | - | 25.14M | 33.56M | 38.16M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -86.83000M | -5.32300M | -18.24700M | -0.77700M | -0.13300M |
| Change to liabilities | 46.55M | 17.93M | -3.62300M | -0.38800M | 6.06M |
| Total cashflows from investing activities | -86.83000M | -5.32300M | -18.24700M | -0.77700M | -0.13300M |
| Net borrowings | 11.40M | -8.00000M | -5.00000M | -6.32600M | -3.75000M |
| Total cash from financing activities | -6.20900M | -28.39200M | -37.87000M | -24.22500M | -88.11700M |
| Change to operating activities | 19.80M | 3.68M | 4.63M | -1.37300M | 12.40M |
| Net income | 35.64M | -8.62700M | 11.99M | 14.31M | 31.90M |
| Change in cash | -42.33800M | -5.49600M | -6.62000M | 30.98M | -35.86600M |
| Begin period cash flow | 97.66M | 103.16M | 109.78M | 78.79M | 114.66M |
| End period cash flow | 55.32M | 97.66M | 103.16M | 109.78M | 78.79M |
| Total cash from operating activities | 50.70M | 28.22M | 49.50M | 55.99M | 52.38M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 12.02M | 3.76M | 4.77M | 4.65M | 3.67M |
| Other cashflows from investing activities | -86.65200M | -5.00000M | -17.50000M | -17.50000M | -17.50000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -8.33900M | -13.83300M | -1.50900M | 1.74M | -5.55600M |
| Change to account receivables | -30.83200M | 9.53M | -3.11300M | 18.48M | -12.66500M |
| Sale purchase of stock | -18.00400M | -21.21300M | -34.99900M | -17.96100M | -73.10500M |
| Other cashflows from financing activities | 79.03M | 0.82M | 112.13M | -0.26400M | -11.26200M |
| Change to netincome | 17.73M | 21.42M | 28.55M | 22.15M | 24.32M |
| Capital expenditures | 0.18M | 0.32M | 0.75M | 0.78M | 0.13M |
| Change receivables | -30.83200M | 9.53M | -3.11300M | 18.48M | -12.66500M |
| Cash flows other operating | -22.53600M | -2.43500M | 13.25M | -5.44000M | 4.27M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -42.33800M | -5.49600M | -6.62000M | 30.98M | -35.86600M |
| Change in working capital | -16.40400M | 9.54M | 0.82M | 14.39M | -7.88900M |
| Stock based compensation | 16.45M | 19.55M | 24.76M | 22.00M | 19.08M |
| Other non cash items | 11.31M | 7.61M | 8.68M | 0.48M | 8.09M |
| Free cash flow | 50.52M | 27.90M | 48.75M | 55.21M | 52.25M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EGRX Eagle Pharmaceuticals Inc |
-0.1 15.38% | 0.55 | 4.40 | 11.34 | 0.23 | 0.24 | 0.45 | 2.07 |
| ZTS Zoetis Inc |
-2.975 1.78% | 164.03 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.12 0.42% | 28.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-1.925 1.33% | 142.50 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.07 0.53% | 13.04 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott L. Tarriff | Founder, Pres, CEO & Director | 1960 |
| Mr. Brian Joseph Cahill | Chief Financial Officer | 1969 |
| Mr. Ryan Debski | Exec. VP, Gen. Counsel & Chief Compliance Officer | NA |
| Mr. Daniel O'Connor | Exec. VP, Chief Strategy Officer & Head of Corp. Devel. | 1980 |
| Mr. John Kimmet | Exec. VP of Marketing Oncology & Acute Care | NA |
| Dr. Valentin R. Curt M.D. | Sr. VP of Clinical Drug Devel. | NA |
| Dr. Gaozhong Zhu Ph.D. | Sr. VP of Pharmaceutical Devel. | NA |
| Ms. Debra M. Hussain | Sr. VP & Head of Commercial | NA |
| Mr. Reiner Nowak | Exec. | NA |
| Mr. Michael Graves | Interim Principal Executive Officer & Executive Chairman of the Board | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...